LEQVIO SOLUTION FOR INJECTION IN PREFILLED SYRINGE 284 MG/1.5 ML

NOVARTIS (SINGAPORE) PTE LTD

NOVARTIS (SINGAPORE) PTE LTD

Therapeutic

Prescription Only

INJECTION, SOLUTION

**4 Dosage regimen and administration** **Dosage regimen** The recommended dose of Leqvio is 284 mg administered as a single subcutaneous injection: initially, again at 3 months, followed by every 6 months. _**Missed dose**_ - If a planned dose of Leqvio is missed by less than 3 months, Leqvio should be administered and dosing maintained according to the patient’s original schedule. - If a planned dose of Leqvio is missed by more than 3 months, a new dosing schedule should be started – Leqvio should be administered initially, again at 3 months, followed by every 6 months. **Treatment Transition from PCSK9 Inhibitor Monoclonal Antibody** Leqvio can be administered immediately after the last dose of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor monoclonal antibody. To maintain LDL-C lowering, it is recommended that Leqvio is administered within 2 weeks after the last dose of a PCSK9 inhibitor monoclonal antibody. **Special populations** **Renal impairment** No dose adjustment is necessary for patients with renal impairment (mild, moderate or severe) or end-stage renal disease. There is limited experience with inclisiran in patients with severe renal impairment. Inclisiran should be used with caution in these patients. If administering Leqvio to patients on hemodialysis, hemodialysis should not be performed for at least 72 hours after Leqvio dosing (see section 11 Clinical pharmacology – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). **Hepatic impairment** No dose adjustment is necessary for patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment. Patients with severe hepatic impairment (Child-Pugh class C) have not been studied. **Pediatric patients (below 18 years)** The safety and efficacy of Leqvio in patients below 18 years of age have not been established. **Geriatric patients (65 years of age or above)** No dose adjustment is necessary in patients 65 years of age or above. **Method of administration** Leqvio is intended for administration by a healthcare professional. Leqvio is for subcutaneous injection into the abdomen. Injections should not be given into areas of active skin disease or injury such as sunburns, skin rashes, inflammation, or skin infections. Leqvio should be inspected visually for particulate matter prior to administration. If the solution contains visible particulate matter, the solution should not be used. Each 284 mg dose is administered using a single pre-filled syringe. Each pre-filled syringe is for single use only. There are two types of pre-filled syringes (one with needle guard, one without needle guard). For the instructions for use for the pre-filled syringe with needle guard, see section 14 Pharmaceutical information – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Not all presentations are available in all countries.